Toward a bioengineered heparin challenges and strategies for metabolic engineering of mammalian cells

Bioengineered

Volumn 3, Issue 4, 2012, Pages

  Baik, Jong Youn ^a   Wang, Clifford L ^b   Yang, Bo ^c   Linhardt, Robert J ^c   Sharfstein, Susan T ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b Stanford University   (United States)

^c Research Rensselaer Polytechnic Institute   (United States)

Author keywords

Anticoagulant; Chinese hamster ovary cells; Heparin; LC MS; Metabolic engineering; Transcriptional regulation; Translational regulation

Indexed keywords

HEPARAN SULFATE 3 O SULFOTRANSFERASE; HEPARIN; N SULFOTRANSFERASE; PENTASACCHARIDE; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SULFATION; DRUG SYNTHESIS; ENZYME ACTIVITY; GENETIC ENGINEERING; GOLGI COMPLEX; MAMMAL CELL; METABOLIC ENGINEERING; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALIA; CRICETULUS GRISEUS; MAMMALIA;

EID: 84877706650     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bioe.20902     Document Type: Article

References (29)

1. Bigelow WG. Mysterious Heparin: The Key to Open Heart Surgery. Toronto-Montreal: McGraw-Hill Ryerson 1990.
2. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of heparin. Nat Prod Rep 2009; 26:313-21; PMID:19240943; http://dx.doi.org/10.1039/b819896a.
3. Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 1999; 25:5-16; PMID:10549711.
4. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26:669-75; PMID:18437154; http://dx.doi.org/10.1038/nbt1407.
5. Liu R, Xu Y, Chen M, Weïwer M, Zhou X, Bridges AS, et al. Chemoenzymatic design of heparan sulfate oligosaccharides. J Biol Chem 2010; 285:34240-9; PMID:20729556; http://dx.doi.org/10.1074/jbc.M110.159152.
6. Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, et al. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science 2011; 334:498-501; PMID:22034431; http://dx.doi.org/10.1126/science.1207478.
7. Masuko S, Bera S, Green DE, Weïwer M, Liu J, DeAngelis PL, et al. Chemoenzymatic synthesis of uridine diphosphate-GlcNAc and uridine diphosphate-GalNAc analogs for the preparation of unnatural glycosaminoglycans. J Org Chem 2012; 77:1449-56; PMID:22239739; http://dx.doi.org/10.1021/jo202322k.
8. Wang Z, Yang B, Zhang Z, Ly M, Takieddin M, Mousa S, et al. Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol 2011; 91:91-9; PMID:21484210; http://dx.doi.org/10.1007/s00253-011-3231-5.
9. Marcum JA, Rosenberg RD. Anticoagulantly active heparan sulfate proteoglycan and the vascular endothelium. Semin Thromb Hemost 1987; 13:464-74; PMID:2962288; http://dx.doi.org/10.1055/s-2007-1003523.
10. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41:391-412; PMID:12491369; http://dx.doi.org/10.1002/1521-3773(20020201)41:3390::AIDANIE3903.0.CO;2-B.
11. Muszbek L, Bereczky Z, Kovács B, Komáromi I. Antithrombin deficiency and its laboratory diagnosis. Clin Chem Lab Med 2010; 48:67-78; PMID:21062218; http://dx.doi.org/10.1515/cclm.2010.368.
12. Robinson HC, Horner AA, Höök M, Ogren S, Lindahl U. A proteoglycan form of heparin and its degradation to single-chain molecules. J Biol Chem 1978; 253:6687-93; PMID:690122.
13. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002; 71:435-71; PMID:12045103; http://dx.doi.org/10.1146/annurev.bio-chem.71.110601.135458.
14. Casu B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 1985; 43:51-134; PMID:3913287; http://dx.doi.org/10.1016/S0065-2318(08)60067-0.
15. Nairn AV, Kinoshita-Toyoda A, Toyoda H, Xie J, Harris K, Dalton S, et al. Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J Proteome Res 2007; 6:4374-87; PMID:17915907; http://dx.doi.org/10.1021/pr070446f.
16. Baik JY, Gasimli L, Yang B, Datta P, Zhang F, Glass CA, et al. Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin. Metab Eng 2012; 14:81-90; PMID:22326251; http://dx.doi.org/10.1016/j.ymben.2012.01.008.
17. Sugahara K, Kitagawa H. Heparin and heparin sulfate biosynthesis. IUBMB Life 2002; 54:163-75; PMID:12512855; http://dx.doi.org/10.1080/15216540214928.
18. Xu X, Nagarajan H, Lewis NE, Pan S, Cai Z, Liu X, et al. The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line. Nat Biotechnol 2011; 29:735-41; PMID:21804562; http://dx.doi.org/10.1038/nbt.1932.
19. Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68:729-77; PMID:10872465; http://dx.doi.org/10.1146/annurev.biochem.68.1.729.
20. Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells 2007; 24:153-66; PMID:17978567.
21. Yang B, Weyers A, Baik JY, Sterner E, Sharfstein S, Mousa SA, et al. Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem 2011; 415:59-66; PMID:21530482; http://dx.doi.org/10.1016/j.ab.2011.04.003.
22. Zhao W, Garron ML, Yang B, Xiao Z, Esko JD, Cygler M, et al. Asparagine 405 of heparin lyase II prevents the cleavage of glycosidic linkages proximate to a 3-O-sulfoglucosamine residue. FEBS Lett 2011; 585:2461-6; PMID:21741976; http://dx.doi.org/10.1016/j.febslet.2011.06.023.
23. Pitera DJ, Paddon CJ, Newman JD, Keasling JD. Balancing a heterologous mevalonate pathway for improved isoprenoid production in Escherichia coli. Metab Eng 2007; 9:193-207; PMID:17239639; http://dx.doi.org/10.1016/j.ymben.2006.11.002.
24. Alper H, Fischer C, Nevoigt E, Stephanopoulos G. Tuning genetic control through promoter engineering. Proc Natl Acad Sci USA 2005; 102:12678-83; PMID:16123130; http://dx.doi.org/10.1073/pnas.0504604102.
25. Michalodimitrakis K, Isalan M. Engineering prokaryotic gene circuits. FEMS Microbiol Rev 2009; 33:27-37; PMID:19016883; http://dx.doi.org/10.1111/j.1574-6976.2008.00139.x.
26. Peacock RWS, Sullivan KA, Wang CL. Tetracycline-Regulated Expression Implemented through Transcriptional Activation Combined with Proximal and Distal Repression. ACS Synthetic Biology 2012; 1:156-62; http://dx.doi.org/10.1021/sb200029a.
27. Ferreira JP, Peacock RWS, Lawhorn IEB, Wang CL. Modulating ectopic gene expression levels by using retroviral vectors equipped with synthetic promoters. Syst Synth Biol 2011; 5:131-8; http://dx.doi.org/10.1007/s11693-011-9089-0.
28. Ferreira JP, Lawhorn IE, Peacock RW, Wang CL. Quantitative assessment of Ras overexpression via shotgun deployment of vectors utilizing synthetic promoters. Integr Biol (Camb) 2012; 4:108-14; PMID:22108821; http://dx.doi.org/10.1039/c1ib00082a.
29. Busse M, Feta A, Presto J, Wilén M, Grønning M, Kjellén L, et al. Contribution of EXT1, EXT2 and EXTL3 to heparan sulfate chain elongation. J Biol Chem 2007; 282:32802-10; PMID:17761672; http://dx.doi.org/10.1074/jbc.M703560200.